Patients with diabetes and a history of metabolic surgery had significantly fewer heart attacks, strokes, hospitalizations and death compared to matched patients who did not have the surgery, according to a new study presented here today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2023 Annual Scientific Meeting.
Ribon Therapeutics rids preclinical work, trims staff to focus on two clinical PARP inhibitors
Ribon Therapeutics, a biotech looking to make next-generation oral PARP inhibitors, has ended preclinical and platform work to focus on two clinical programs. “Cuts across
July 29, 2023